Metformin Nanodelivery System Alleviates Morphine-Induced Analgesic Tolerance via Inhibiting the TXNIP/NLRP3/GSDMD Axis
Abstract
Morphine-induced analgesic tolerance limits its clinical use. This study shows that metformin alleviates such tolerance by inhibiting the TXNIP/NLRP3/GSDMD axis, reducing microglial activation and proinflammatory cytokines in CD-1 mice (metformin 200 mg/kg i.p.; morphine 10 mg/kg s.c.) and BV-2 cells (metformin 100 μM; morphine 200 μM). TXNIP is critical, as its overexpression weakens metformin's effect. The TXNIP siRNA/metformin coloaded TM@ZIF-8/HA nanosystem enhances efficacy via pH-responsive, CD44-targeted delivery with good biocompatibility, providing a perioperative pain management strategy.
Read the paper
Related studies
- Metformin as an adjuvant in breast cancer treatment
- Metformin Lysosomal Targeting: A Novel Aspect to Be Investigated for Metformin Repurposing in Neurodegenerative Diseases?
- Aberrant HSF1 signaling activation underlies metformin amelioration of myocardial infarction in mice
- Metformin induces ZFP36 by mTORC1 inhibition in cervical cancer-derived cell lines
- Protein Interaction Network for Identifying Vascular Response of Metformin (Oral Antidiabetic)
- Preventing Long COVID With Metformin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.